Kathryn Creagh
Adult Health · Stamford, CTNPI 1588088355
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 444 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 444 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Merck$783
- Johnson & Johnson$763
- Boehringer Ingelheim$761
- Pfizer$737
- E.r. Squibb & Sons, L.L.C.$734
- plus $5K from 25 others
What the payments were for
- Food & beverage$9,696100%
- Education$480%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 57 | $1,205 |
| Merck | 35 | $783 |
| Johnson & Johnson | 32 | $763 |
| Boehringer Ingelheim | 32 | $761 |
| Pfizer | 35 | $737 |
| E.r. Squibb & Sons, L.L.C. | 35 | $734 |
| Alnylam Pharmaceuticals Inc. | 31 | $685 |
| Amgen | 25 | $591 |
| AstraZeneca | 32 | $559 |
| Esperion Therapeutics, Inc. | 26 | $547 |
| Novo Nordisk | 17 | $373 |
| Abbott | 10 | $351 |
| Amarin Pharma, Inc. | 18 | $343 |
| Lexicon Pharmaceuticals, Inc. | 9 | $216 |
| Biotronik Inc. | 5 | $162 |
| Kowa Pharmaceuticals America, Inc. | 10 | $153 |
| Scpharmaceuticals Inc. | 7 | $127 |
| Bridgebio Pharma, Inc. | 5 | $120 |
| Boston Scientific | 5 | $119 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $82 |
| Sanofi-aventis U.S. LLC | 2 | $51 |
| Bayer | 2 | $47 |
| Abiomed | 2 | $46 |
| Baxter Healthcare | 1 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $26 |
| Philips North America LLC | 1 | $24 |
| Mannkind Corporation | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $15 |
| Medicomp Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$155
- Acticor 7 VR-T DX$119
How this compares
$9,744 in reported general payments places this provider in the 90th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $63,478 |
| Repatha SureclickEvolocumab | 21 | $30,774 |
| EntrestoSacubitril/Valsartan | 19 | $30,620 |
| XareltoRivaroxaban | 25 | $30,275 |
| JardianceEmpagliflozin | 16 | $25,747 |
| Metoprolol Succinate | 116 | $1,636 |
| Nebivolol Hcl | 15 | $1,365 |
| Rosuvastatin Calcium | 99 | $955 |
| Valsartan | 42 | $688 |
| Losartan Potassium | 43 | $625 |
| Atorvastatin Calcium | 57 | $597 |
| Digoxin | 21 | $595 |
| Amlodipine Besylate | 74 | $562 |
| Olmesartan Medoxomil | 11 | $477 |
| Torsemide | 21 | $391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $737 | $63,47865 claims |
| NovartisEntresto | $1,205 | $30,62019 claims |
| Johnson & JohnsonXarelto | $763 | $30,27525 claims |
| Boehringer IngelheimJardiance | $761 | $25,74716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 418 adult health providers in Connecticut.
Other adult health in Stamford
- Amanda PucciStamford$10K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.